Lipocine Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 10, 2023. This is an annual report, not a standalone fourth-quarter report. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products. Its U.S. licensee launched TLANDO, an oral testosterone replacement therapy, in June 2022 following FDA approval in March.
Financial performance and position
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $0.5 million | $16.1 million |
| Research and development expense | $8.6 million | $7.7 million |
| General and administrative expense | $4.1 million | $5.3 million |
| Operating income (loss) | $(12.1) million | $3.1 million |
| Net income (loss) | $(10.8) million | $(0.6) million |
| Basic loss per share | $(0.12) | $(0.01) |
| Cash used in operating activities | $12.0 million | $4.4 million |
- 2022 revenue was the $500,000 non-refundable fee from Antares for extending its option to license LPCN 1111; Antares did not exercise the option. 2021 revenue primarily reflected the TLANDO license agreement, including an $11 million upfront payment, minimum royalties, and transferred inventory.
- Lipocine reported no product-sales revenue in either year. Product gross margin is therefore not meaningful from the disclosed results; 2022 sales-based royalty revenue was zero.
- At year-end, cash and cash equivalents were $3.1 million and marketable securities were $29.4 million, or $32.5 million combined. Current assets were $34.1 million versus current liabilities of $1.7 million.
- Total liabilities were $1.9 million. The SVB loan was repaid in full in June 2022; no debt was reported at year-end.
- Accumulated deficit was $183.4 million. The auditor issued an unmodified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not audit internal control effectiveness.
Changes and significant events
- Revenue fell from $16.1 million to $0.5 million, and net loss widened from $0.6 million to $10.8 million. The prior-year result included substantial non-recurring license revenue and a $4.0 million Clarus litigation settlement expense.
- R&D expense increased $0.9 million, mainly due to the LPCN 1148 Phase 2 study and LPCN 1111 manufacturing scale-up. G&A expense declined $1.3 million, principally as legal expenses related to the Clarus dispute fell.
- Operating cash use increased to $12.0 million. Investing cash provided $14.3 million, mainly from maturities of marketable securities; financing cash used $2.1 million, largely for SVB loan repayments and the $650,000 final payment charge.
- The Clarus dispute was settled; a 2022 amendment reduced remaining settlement payments by $250,000, and Lipocine paid $1.25 million in May 2022. No future royalties are due to either party. A separate shareholder securities class action remained unresolved; the company recorded no liability, citing uncertainty that a loss was probable or estimable.
- Antares became a Halozyme subsidiary in May 2022. The TLANDO agreement provides for tiered U.S. royalties, potential sales milestones up to $160 million, and conditional $5 million payments in each of 2025 and 2026.
Outlook, risks, and contingencies
- Management estimated existing resources would fund planned operations through at least March 31, 2024, based on assumptions. It expects to need additional capital to support operations and development; financing may be unavailable or dilutive, and failure to raise funds could impair its ability to continue as a going concern.
- Management expected LPCN 1154 pilot PK-bridge results in the first half of 2023 and planned a Phase 2 proof-of-concept study for LPCN 2101 in 2023, subject to resources. LPCN 1148 Phase 2 24-week results were expected mid-2023 after enrollment completed in Q4 2022.
- For LPCN 1144, FDA feedback included a recommendation for a Phase 2 dose-ranging study to identify an optimal dose before a pivotal study. Further development of several non-core candidates is dependent on finding partners; no such arrangements were assured.
- TLANDO’s commercialization and royalty potential depend on Halozyme’s efforts, market acceptance, reimbursement, competition, and required post-marketing studies. The product label includes a boxed warning and blood-pressure-related precautions; negative post-marketing findings could affect commercialization.
- Nasdaq had granted Lipocine an extension through June 5, 2023 to regain compliance with the $1.00 minimum bid-price requirement. In March 2023, after year-end, the board declared a Series B preferred-stock dividend with voting rights limited to reverse-stock-split and related adjournment proposals.
- Other key risks include clinical and regulatory uncertainty, dependence on third-party manufacturers and CROs, reliance on limited suppliers for key ingredients, inability to secure partners, patent risks, litigation, and need for additional financing. The filing provides no revenue or profitability guidance.
Important facts for investors to verify
- Whether TLANDO sales generate royalties and whether the licensee satisfies contractual conditions for future payments.
- Actual cash burn, investment maturities, and financing needs relative to management’s March 31, 2024 runway estimate.
- Results and timing of LPCN 1154, LPCN 2101, and LPCN 1148 studies, and whether funding or partnerships permit planned development.
- Progress on Nasdaq bid-price compliance and the subsequent reverse-stock-split process, including the Series B preferred-stock voting mechanics.
- Status and potential exposure from the unresolved shareholder class action and any updates to other legal or regulatory matters.